ArticleDiabetes research and clinical practice2007
Individualized pharmacokinetic risk assessment for development of diabetes in high risk population.
Article in Diabetes research and clinical practice, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
aimThe objective of this study is to propose a non-parametric pharmacokinetic prediction model that addresses the individualized risk of developing type-2 diabetes in subjects with family history of type-2 diabetes.
methodAll selected 191 healthy subjects had both parents as type-2 diabetic. Glucose was administered intravenously (0.5 g/kg body weight) and 13 blood samples taken at specified times were analyzed for plasma insulin and glucose concentrations. All subjects were followed for an average of 13-14 years for diabetic or normal (non-diabetic) outcome.
resultsThe new logistic regression model predicts the development of diabetes based on body mass index and only one blood sample at 90 min analyzed for insulin concentration. Our model correctly identified 4.5 times more subjects (54% versus 11.6%) predicted to develop diabetes and more than twice the subjects (99% versus 46.4%) predicted not to develop diabetes compared to current non-pharmacokinetic probability estimates for development of type-2 diabetes.
conclusionOur model can be useful for individualized prediction of development of type-2 diabetes in subjects with family history of type-2 diabetes. This improved prediction may be an important mediating factor for better perception of risk and may result in an improved intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.